These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26093494)

  • 1. Quantitative kinetic analysis of PET amyloid imaging agents [(11)C]BF227 and [(18)F]FACT in human brain.
    Shidahara M; Watabe H; Tashiro M; Okamura N; Furumoto S; Watanuki S; Furukawa K; Arakawa Y; Funaki Y; Iwata R; Gonda K; Kudo Y; Arai H; Ishiwata K; Yanai K
    Nucl Med Biol; 2015 Sep; 42(9):734-44. PubMed ID: 26093494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic Evaluation of the Tau PET Radiotracer
    Wooten DW; Guehl NJ; Verwer EE; Shoup TM; Yokell DL; Zubcevik N; Vasdev N; Zafonte RD; Johnson KA; El Fakhri G; Normandin MD
    J Nucl Med; 2017 Mar; 58(3):484-491. PubMed ID: 27660144
    [No Abstract]   [Full Text] [Related]  

  • 3. Amyloid deposits and response to shunt surgery in idiopathic normal-pressure hydrocephalus.
    Hiraoka K; Narita W; Kikuchi H; Baba T; Kanno S; Iizuka O; Tashiro M; Furumoto S; Okamura N; Furukawa K; Arai H; Iwata R; Mori E; Yanai K
    J Neurol Sci; 2015 Sep; 356(1-2):124-8. PubMed ID: 26095458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vivo Comparison of Tau Radioligands
    Betthauser TJ; Lao PJ; Murali D; Barnhart TE; Furumoto S; Okamura N; Stone CK; Johnson SC; Christian BT
    J Nucl Med; 2017 Jun; 58(6):996-1002. PubMed ID: 27856627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Evaluation and Quantification of
    Khanapur S; van Waarde A; Dierckx RA; Elsinga PH; Koole MJ
    J Nucl Med; 2017 Mar; 58(3):466-472. PubMed ID: 27789720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.
    Jonasson M; Wall A; Chiotis K; Saint-Aubert L; Wilking H; Sprycha M; Borg B; Thibblin A; Eriksson J; Sörensen J; Antoni G; Nordberg A; Lubberink M
    J Nucl Med; 2016 Apr; 57(4):574-81. PubMed ID: 26795290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand.
    Cselényi Z; Jönhagen ME; Forsberg A; Halldin C; Julin P; Schou M; Johnström P; Varnäs K; Svensson S; Farde L
    J Nucl Med; 2012 Mar; 53(3):415-24. PubMed ID: 22323782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parametric imaging and quantitative analysis of the PET amyloid ligand [(18)F]flutemetamol.
    Heurling K; Buckley C; Van Laere K; Vandenberghe R; Lubberink M
    Neuroimage; 2015 Nov; 121():184-92. PubMed ID: 26209803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains.
    Becker GA; Ichise M; Barthel H; Luthardt J; Patt M; Seese A; Schultze-Mosgau M; Rohde B; Gertz HJ; Reininger C; Sabri O
    J Nucl Med; 2013 May; 54(5):723-31. PubMed ID: 23471310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [
    Guehl NJ; Wooten DW; Yokell DL; Moon SH; Dhaynaut M; Katz S; Moody KA; Gharagouzloo C; Kas A; Johnson KA; El Fakhri G; Normandin MD
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2099-2111. PubMed ID: 31332496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer's disease.
    Ahmad R; Postnov A; Bormans G; Versijpt J; Vandenbulcke M; Van Laere K
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2219-2227. PubMed ID: 27488857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of the Clinical SUV Ratio in Amyloid PET Imaging Using a Biomathematic Modeling Approach Toward the Efficient Development of a Radioligand.
    Arakawa Y; Nai Y; Shidahara M; Furumoto S; Seki C; Okamura N; Tashiro M; Kudo Y; Yanai K; Gonda K; Watabe H
    J Nucl Med; 2017 Aug; 58(8):1285-1292. PubMed ID: 28062596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic Modeling of the Tau PET Tracer
    Barret O; Alagille D; Sanabria S; Comley RA; Weimer RM; Borroni E; Mintun M; Seneca N; Papin C; Morley T; Marek K; Seibyl JP; Tamagnan GD; Jennings D
    J Nucl Med; 2017 Jul; 58(7):1124-1131. PubMed ID: 27908967
    [No Abstract]   [Full Text] [Related]  

  • 14. Multi-graphical analysis of dynamic PET.
    Zhou Y; Ye W; Brasić JR; Wong DF
    Neuroimage; 2010 Feb; 49(4):2947-57. PubMed ID: 19931403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.
    Baker SL; Lockhart SN; Price JC; He M; Huesman RH; Schonhaut D; Faria J; Rabinovici G; Jagust WJ
    J Nucl Med; 2017 Feb; 58(2):332-338. PubMed ID: 27587706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebellar Amyloid-β Plaques: How Frequent Are They, and Do They Influence 18F-Florbetaben SUV Ratios?
    Catafau AM; Bullich S; Seibyl JP; Barthel H; Ghetti B; Leverenz J; Ironside JW; Schulz-Schaeffer WJ; Hoffmann A; Sabri O
    J Nucl Med; 2016 Nov; 57(11):1740-1745. PubMed ID: 27363836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.
    Fodero-Tavoletti MT; Mulligan RS; Okamura N; Furumoto S; Rowe CC; Kudo Y; Masters CL; Cappai R; Yanai K; Villemagne VL
    Eur J Pharmacol; 2009 Sep; 617(1-3):54-8. PubMed ID: 19576880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET.
    Gallezot JD; Bottlaender M; Grégoire MC; Roumenov D; Deverre JR; Coulon C; Ottaviani M; Dollé F; Syrota A; Valette H
    J Nucl Med; 2005 Feb; 46(2):240-7. PubMed ID: 15695782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 18F-labeled BF-227 derivative as a potential radioligand for imaging dense amyloid plaques by positron emission tomography.
    Furumoto S; Okamura N; Furukawa K; Tashiro M; Ishikawa Y; Sugi K; Tomita N; Waragai M; Harada R; Tago T; Iwata R; Yanai K; Arai H; Kudo Y
    Mol Imaging Biol; 2013 Aug; 15(4):497-506. PubMed ID: 23362000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
    Joshi AD; Pontecorvo MJ; Clark CM; Carpenter AP; Jennings DL; Sadowsky CH; Adler LP; Kovnat KD; Seibyl JP; Arora A; Saha K; Burns JD; Lowrey MJ; Mintun MA; Skovronsky DM;
    J Nucl Med; 2012 Mar; 53(3):378-84. PubMed ID: 22331215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.